Last updated: February 21, 2026
What Is NDC 00169-2660?
NDC 00169-2660 refers to a specific drug product listed in the United States' National Drug Code database. This code corresponds to Prolia (denosumab), a monoclonal antibody indicated for osteoporosis, metastatic bone disease, and certain other bone-related conditions.
Market Size and Demand Drivers
Global Osteoporosis Market
- The osteoporosis market was valued at approximately USD 9 billion in 2021.
- Compound annual growth rate (CAGR) is projected at 4-5% through 2028 (Fortune Business Insights, 2022).
Key Indications and Prescribing Patterns
- Prolia's primary approval in osteoporosis for postmenopausal women and men at high fracture risk.
- Growing prevalence of osteoporosis correlates with aging populations globally.
- Estimated 10 million Americans have osteoporosis; an additional 44 million have low bone mass (National Osteoporosis Foundation, 2021).
Competitive Landscape
- Major competitors: BMD (Bone Mineral Density) therapies such as bisphosphonates (alendronate, zoledronic acid), anabolic agents (abaloparatide).
- Prolia holds approximately 25-30% market share among injectable bone therapies (EvaluatePharma, 2022).
Market Trends and Growth Projections
- Introduction of biosimilars and generics is limited due to patent protections until 2025.
- New indications in cancer-related bone metastases expand potential use.
- Market growth driven by increasing osteoporosis diagnosis, outpatient adoption, and treatment adherence improvements.
Price Analysis
Historical Pricing
- List Price: In 2022, the wholesale acquisition cost (WAC) for a 60 mg/1.7 mL single-use prefilled syringe was approximately USD 2,100.
- Average Net Price: After rebates and discounts, estimated at USD 1,600–1,800 per dose (IQVIA, 2022).
Pricing Trends
- Slight upward trend over past five years due to manufacturing costs and expanded indications.
- Price discounts offered to large payers and formulary negotiations influence actual transaction prices, reducing net revenue per dose.
Cost-Effectiveness and Reimbursement
- Cost-effectiveness varies; studies cite incremental cost-effectiveness ratios (ICERs) ranging from USD 50,000 to USD 150,000 per quality-adjusted life year (QALY), depending on patient profile and comparator (Rizzo et al., 2020).
- Reimbursement primarily through Medicare, Medicaid, and private insurers, with formulary placement impacting access and pricing.
Future Price Projections (Next 3–5 Years)
| Year |
Expected List Price (USD) |
Notes |
| 2023 |
2,100 |
Stable, subject to minor inflation |
| 2024 |
2,200 |
Potential to increase with new indications |
| 2025 |
2,300 |
Patent expiry approaches, biosimilar entry |
| 2026 |
1,700–2,000 (biosimilar) |
Price reduction anticipated due to biosimilars |
Market competition post-patent expiry expected to push net prices downward, potentially reducing revenue by 20–30%. Manufacturers may implement pricing strategies to maintain market share, such as patient assistance programs or negotiated discounts.
Regulatory and Policy Influences
- Patent protections expire in the U.S. in 2025, opening pathway for biosimilars.
- CMS and private insurers focus on cost containment, incentivizing lower prices.
- FDA approval of biosimilar candidates could increase market penetration and further pressure prices.
Summary
- The current market for Prolia (NDC 00169-2660) is stable, with annual sales near USD 1.6–1.8 billion in the U.S.
- Pricing remains relatively fixed, with small upward adjustments; significant reductions expected after biosimilar entry.
- Market growth depends on osteoporosis prevalence, new indications, and biosimilar competition.
Key Takeaways
- Market size approximates USD 9 billion globally, with a compound growth rate of 4–5%.
- Current prices hover around USD 2,100 per dose; net prices are lower due to discounts.
- Patent expiration in 2025 will likely lead to a substantial price decrease driven by biosimilar competition.
- Reimbursement policies and formulary strategies critically influence revenue streams.
- Prolia’s future market viability hinges on expanding indications and biosimilar adoption.
FAQs
Q1: When will biosimilars for Prolia enter the U.S. market?
A: Expected after patent expiry in 2025, with potential approvals occurring from late 2024 onward.
Q2: How much can prices decrease with biosimilar competition?
A: Biosimilar entry typically reduces prices by 20–30%, potentially lowering net revenue significantly.
Q3: What factors influence Prolia’s pricing in the U.S.?
A: Rebate negotiations, payer strategies, manufacturing costs, and regulatory changes.
Q4: How is Prolia positioned against other osteoporosis treatments?
A: It holds a significant injectable segment share but faces competition from bisphosphonates and oral therapies.
Q5: Are there new indications that could expand Prolia’s market?
A: Yes, approvals for bone metastases in cancer and other bone disorders are in development.
References
[1] Fortune Business Insights. (2022). Osteoporosis Drugs Market Size, Share & Industry Analysis.
[2] National Osteoporosis Foundation. (2021). Osteoporosis Statistics.
[3] EvaluatePharma. (2022). Market Share Data for Bone Therapies.
[4] IQVIA. (2022). Pharmaceutical Pricing Analysis.
[5] Rizzo, S., et al. (2020). Cost-effectiveness of osteoporosis therapies: a systematic review. Pharmacoeconomics.
